Maftivimab
Maftivimab is a Zaire ebolavirus glycoprotein-directed human monoclonal antibody that is part of the fixed-dose combination atoltivimab/maftivimab/odesivimab that is used for the treatment of Zaire ebolavirus (Ebola virus).[1][2]
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | Zaire ebolavirus |
| Clinical data | |
| Pronunciation | maf tiv' i mab |
| License data |
|
| Drug class | Monoclonal antibody |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6368H9886N1706O2008S46 |
| Molar mass | 143947.83 g·mol−1 |
References
- "FDA Approves First Treatment for Ebola Virus". U.S. Food and Drug Administration (FDA) (Press release). 14 October 2020. Retrieved 14 October 2020.
This article incorporates text from this source, which is in the public domain. - "Regeneron's Antibody Cocktail REGN-EB3 (Inmazeb) is First FDA-Approved Treatment for Ebola (Zaire Ebolavirus)". Regeneron Pharmaceuticals Inc. (Press release). 14 October 2020. Retrieved 14 October 2020.
External links
- "Maftivimab". Drug Information Portal. U.S. National Library of Medicine.
- "Statement on a nonproprietary name adopted by the USAN Council USAN (FG-103) Maftivimab" (PDF).
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.